---
schema_version: "secwatch.filing_event.v1"
accession: "0001720580-26-000054"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2026-09-01T11:02:02+00:00"
generated_at: "2026-09-01T11:05:10.913828+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adicet completes prula-cel SLE study visits; topline due Sept 2026; ADI-212 IND cleared

## Summary
- Prula-cel Phase 1 last patient visit completed; topline data from 22 SLE patients (13 with ≥12 mo follow-up) expected September 2026.
- FDA cleared IND for ADI-212 in mCRPC; Phase 1 enrollment to start 4Q 2026.
- Expanded prula-cel to outpatient setting after FDA alignment; systemic sclerosis update expected Q4 2026.
- In vivo CAR-T platform: first candidate expected in clinic 2H 2027; programs target myeloma, NHL, solid tumors.

## SEC filing metadata
- accession: 0001720580-26-000054
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2026-09-01T11:02:02+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000172058026000054/0001720580-26-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000172058026000054/acet-20260901.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001720580-26-000054
- JSON: https://secwatch.observer/filing/0001720580-26-000054.json
- Plain text: https://secwatch.observer/filing/0001720580-26-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.